Posted in | News | Plastics and Polymers | Business | Petrochemicals

Lummus Technology to Market BP’s Paraxylene Technology

Editorial Checklist Reviewed
Oct 7 2010

CB&I (NYSE:CBI) announced today that Lummus Technology, a CB&I Company, has signed an agreement with BP for the exclusive right to license and market BP’s paraxylene recovery and isomerization technology and catalyst.

CB&I’s Lummus Technology business sector will be responsible for all sales, marketing and licensing activities globally. The terms of the agreement were not disclosed.

“We are pleased to add this innovative and commercially proven technology to our suite of petrochemical processes. This technology marks our entry into the polyester value chain and significantly bolsters our technology portfolio in aromatics,” said Dan McCarthy, President of Lummus Technology.

Source:

http://www.CBI.com/

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
(Logout)
Your comment type
Submit

Sponsored Content

Editorial Highlights

The Current State of the Global Semiconductor Market

The Current State of the Global Semiconductor Market

The global semiconductor market has entered an exciting period. Demand for chip technology is both driving the industry as well as hindering it, with current chip shortages predicted to last for some time. Current trends will likely shape the future of the industry, which is set to continue to show

How are Graphene Batteries Made?

How are Graphene Batteries Made?

The primary distinction between graphene-based batteries and solid-state batteries lies in the composition of either electrode. Although the cathode is commonly changed, carbon allotropes can also be employed in fabricating anodes.

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback